He QJ, Li YF, Zhao LT, Lin CT, Yu CY, Wang D. Recent advances in age-related metabolic dysfunction-associated steatotic liver disease. World J Gastroenterol 2024; 30(7): 652-662 [PMID: 38515956 DOI: 10.3748/wjg.v30.i7.652]
Corresponding Author of This Article
Dan Wang, PhD, Professor, College of Basic Medicine, Beihua University, No. 3999 Binjiangdonglu, Jilin 132013, Jilin Province, China. jljl1215@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Feb 21, 2024; 30(7): 652-662 Published online Feb 21, 2024. doi: 10.3748/wjg.v30.i7.652
Recent advances in age-related metabolic dysfunction-associated steatotic liver disease
Qian-Jun He, Yi-Fei Li, Ling-Tong Zhao, Chun-Tong Lin, Chun-Yan Yu, Dan Wang
Qian-Jun He, Ling-Tong Zhao, Chun-Tong Lin, Chun-Yan Yu, Dan Wang, College of Basic Medicine, Beihua University, Jilin 132013, Jilin Province, China
Yi-Fei Li, Department of Traumatic Surgery, Jilin Central Hospital, Jilin 132001, Jilin Province, China
Author contributions: All authors performed the literature review and wrote the manuscript; He QJ drew and modified the illustrations; Li YF, Yu CY, and Wang D critically reviewed and revised the manuscript.
Supported byJilin Provincial Department of science and Technology, No. YDZJ202301ZYTS112 and No. YDZJ202101ZYTS090; and Jilin Provincial Health and Family Planning Commission, No. 2021JC084.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dan Wang, PhD, Professor, College of Basic Medicine, Beihua University, No. 3999 Binjiangdonglu, Jilin 132013, Jilin Province, China. jljl1215@163.com
Received: November 12, 2023 Peer-review started: November 12, 2023 First decision: December 25, 2023 Revised: December 30, 2023 Accepted: January 22, 2024 Article in press: January 22, 2024 Published online: February 21, 2024 Processing time: 101 Days and 3.9 Hours
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 25% of the world's population and has become a leading cause of chronic liver disease. In recent years, an increasing amount of data suggests that MASLD is associated with aging. As the population ages, age-related MASLD will become a major global health problem. Targeting an aging will become a new approach to the treatment of MASLD. This paper reviews the current studies on the role of aging-related factors and therapeutic targets in MASLD, including: Oxidative stress, autophagy, mitochondrial homeostasis, bile acid metabolism homeostasis, and dysbiosis. The aim is to identify effective therapeutic targets for age-related MASLD and its progression.
Core Tip: Aging is closely associated with metabolic dysfunction-associated steatotic liver disease (MASLD). We will focus on the main features of age-related MASLD, the mechanisms by which age-related factors, such as oxidative stress, autophagy, mitochondrial homeostasis, bile acid metabolism and bacterial dysbiosis induce MASLD, as well as the study of related therapeutic targets.
